21 CFR Part 211 · Current Good Manufacturing Practice for Finished Pharmaceuticals

21 CFR 211.111

Time limitations on production

21 CFR 211.111 is the regulation titled “Time limitations on production” in 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. Since 2021, 1 FDA warning letter has cited it.

Letters citing it
1 since 2021
Jan 1 to Oct 30, 2026
0 against 0 on the same dates in 2025
Most often cited with
21 CFR 1271.10, in 1 letter
Closed out
0% of these letters have a published close-out
See the letter citing 21 CFR 211.111 →

Letters citing it, by year issued

It is a biologics letter. 2026 runs to Oct 30, 2026. Pick a year to see its letters.

  1. 12021
  2. 02022
  3. 02023
  4. 02024
  5. 02025
  6. 02026

The regulation

Read the text of 21 CFR 211.111 (eCFR, as of Sep 1, 2026)

When appropriate, time limits for the completion of each phase of production shall be established to assure the quality of the drug product. Deviation from established time limits may be acceptable if such deviation does not compromise the quality of the drug product. Such deviation shall be justified and documented.

Text from eCFR as of Sep 1, 2026.

Cited alongside it

Regulations that appear in the same letters as 21 CFR 211.111.

Latest letters citing it

The letter citing 21 CFR 211.111 that FDA posted most recently.

See the letter citing 21 CFR 211.111 →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Counts include every citation in a letter, as the Letters filter does. How this database is built.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.